Cited by 915Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Open access

Azzoli, Christopher G., Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H., Laskin, Janessa L., Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pfister, David G., Piantadosi, Steven, Schiller, Joan H., Smith, Reily, Smith, Thomas J., Strawn, John R., Trent, David, Giaccone, Giuseppe·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2009.23.5622PMC PMC2793036

Open this paper in CoChat — free account

Abstract

The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that improve overall survival. Treatments that improve only progression-free survival prompted scrutiny of toxicity and quality of life. For first-line therapy in patients with performance status of 0 or 1, a platinum-based two-drug combination of cytotoxic drugs is recommended. Nonplatinum cytotoxic doublets are acceptable for patients with contraindications to platinum therapy. For patients with performance status of 2, a single cytotoxic drug is sufficient. Stop first-line cytotoxic chemotherapy at disease progression or after four cycles in patients who are not responding to treatment. Stop two-drug cytotoxic chemotherapy at six cycles even in patients who are responding to therapy. The first-line use of gefitinib may be recommended for patients with known epidermal growth factor receptor (EGFR) mutation; for negative or unknown EGFR mutation status, cytotoxic chemotherapy is preferred. Bevacizumab is recommended with carboplatin-paclitaxel, except for patients with certain clinical characteristics. Cetuximab is recommended with cisplatin-vinorelbine for patients with EGFR-positive tumors by immunohistochemistry. Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy. Erlotinib is recommended as third-line therapy for patients who have not received prior erlotinib or gefitinib. Data are insufficient to recommend the routine third-line use of cytotoxic drugs. Data are insufficient to recommend routine use of molecular markers to select chemotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.23.5622

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655

Flagged first, then by citations

Show all 218 references

2 of the 218 references couldn’t be matched to a known paper.

Research works printed but not linked: 7

10.1200/jco.2002.20.5.1335 · DOI
Lynch TJ, Presented at the 12th World Conference on Lung Cancer
Lord RV, 2002, Clin Cancer Res, 8, 2286
Mihaylova Z, 2007, J BUON, 12, 105
Langer CJ, 2004, Oncology, 18, 17
Brose MS, 2002, Cancer Res, 62, 6997
Suzuki Y, 1990, Oncogene, 5, 1037

Sorted by citations

Items 801–900 of 911

Chemotherapy
Januszewski, A. P., & Popat, S. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.10010514 · Cited by 1
Citizenship in Our Profession
Droller, M. J. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.07.009 · Cited by 1
Reply to S. Barni et al, K.R. Dearing et al, and N. Murray
Paz-Ares, L. G., de Marinis, F., Visseren‐Grul, C., & Gridelli, C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6011 · Cited by 1
Lung cancer – ASCO 2010
Pall, G. (2010) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-010-0228-1 · Cited by 1
Maintenance therapies in advanced non-small-cell lung cancer
Lebovic, D. J., Chiappori, A., & Gray, J. E. (2010) · Therapy · doi:10.2217/thy.10.85 · Cited by 1
Molecular Diagnostics Testing for Lung Adenocarcinoma
Sholl, L. M., & Lindeman, N. I. (2010) · Pathology Case Reviews · doi:10.1097/pcr.0b013e3181e71270 · Cited by 1
Personalized medicine in the treatment of advanced nonsmall cell lung cancer
Gridelli, C. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834ea6d7 · Cited by 1
Small Step for Geriatric Oncology That Could Have Been a Giant Leap
Nipp, R. D., & Abel, G. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.0446 · Cited by 1
Molecular subtypes of non-small-cell lung cancer
Stinchcombe, T. E. (2013) · doi:10.2217/ebo.12.201 · Cited by 1
Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilitiesPreprint
Esposito, R., Polidori, T., Meise, D. F., Pulido-Quetglas, C., Chouvardas, P., Forster, S., Schaerer, P., Kobel, A., Schlatter, J., Roemmele, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.19.464956 · Cited by 2
First-Line Treatment and the New Paradigm of Histology-Based Treatment
Gridelli, C., Rossi, A., & Maione, P. (2013) · Springer eBooks · doi:10.1007/978-0-85729-793-8_14
Erhaltungstherapie oder „treatment holiday“ nach Erstlinientherapie
Serke, M. H. (2011) · Der Onkologe · doi:10.1007/s00761-011-2037-5
Chemotherapy for lung cancer: Determinants of guideline adherence and associated patient outcomes
Salloum, R. G. (2011) · Human Biology
Novel Clinical Trial Designs for Metastatic Lung Cancer
Papadimitrakopoulou, V. A. (2014) · Lung Cancer · doi:10.1002/9781118468791.ch31
HIV and Lung Cancer
Okuma, Y., Yanagisawa, N., Hosomi, Y., Ajisawa, A., & Shibuy, M. (2011) · InTech eBooks · doi:10.5772/19974
Is There a Role for Neoadjuvant Chemotherapy in Older Patients?
Navarro, A., & Felip, E. (2013) · Springer eBooks · doi:10.1007/978-0-85729-793-8_10
Cáncer de pulmón de célula no pequeña ALK positivo. Prevalencia y características. La inmunohistoquímica como método diagnóstico.
Martínez, P. (2015) · TDX (Tesis Doctorals en Xarxa)
Nonradiological Treatment for Lung Tumors
Dvořák, T., & DiPetrillo, T. A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1469-9_14
Evidence-based Anticancer Materia Medica for Lung Cancer
Saw, C. L. L., Chew, L. S. T., & Cai, X. G. (2011) · Evidence-based anticancer complementary and alternative medicine · doi:10.1007/978-94-007-1983-5_1
Konsolidujące leczenie systemowe w zaawansowanym niedrobnokomórkowym raku płuca
Duchnowska, R. (2010) · Advances in respiratory medicine · doi:10.5603/arm.27699
Antiangiogenesis and Future Combinations with Anti-Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer
Kim, E. S. (2015) · American Journal of Hematology / Oncology®
Guías de tratamiento médico del cáncer de pulmón de células no pequeñas en el ISSSTE (segunda parte)
Solís, A. A. E. V., Hernández, C. A. H., Sarvide, F. A., & Franco-González, E. E. (2013) · Revista de especialidades m�dico-quir�rgicas
Importancia clínica de los micrornas de la vía de p53 en cáncer de pulmón no microcítico: miR-34a y miR-16
Martín, E. G. (2011) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Targeted Therapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer—Patient Selection Changes the Fate of Gefitinib
Locke, S. R. A. I. (2010) · Clinical Medicine Reviews in Oncology · doi:10.4137/cmro.s3276
Maintenance Therapy of Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer—Role of Pemetrexed
Reinmuth, M. K. A. N. (2010) · Clinical Medicine Reviews in Oncology · doi:10.4137/cmro.s5592
The optimum duration of front-line chemotherapy
Kotsakis, A. P., & Georgoulias, V. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70434-6
Treatment of Non-Small Cell Lung Cancer: Focus on Pemetrexed Disodium
Feliciano, J. L., & Patel, J. D. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s5262
Cancer bronchique non à petites cellules: la 2e ligne et au-delà
Teixeira, L., Staudacher, L., Kempf, E., Durand, C., Rousseau-Bussac, G., Jagot, J.-L., Beuzelin, C., Salmerón, S., & Trédaniel, J. (2011) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(11)70125-2
Analysis of prognostic factors for overall survival in patients with advanced non-small cell lung cancer treated with second line chemotherapy
Rančić, M., Ristić, L., Čekić, M., & Pejčić, T. (2013) · Advances in Lung Cancer · doi:10.4236/alc.2013.23007
Traitement des CBNPC au stade métastatique. Acquis et bonnes pratiques
Pérol, M. (2013) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(13)70436-1
A case of advanced lung cancer treated by surgery followed by adjuvant combination therapy of gefitinib and interleukin-2 lymphokine-activated killer cell immunotherapy
Ayabe, T., Shimizu, T. M., Tomita, M., Kushima, Y., & Onitsuka, T. (2012) · Annals of Cancer Research and Therapy · doi:10.4993/acrt.20.11
Effectiveness of maintenance treatments for nonsmall cell lung cancer
Price, K. A. R., Eadens, & Robinson (2011) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s12507
Dynamic Contrast-Enhanced CT in Advanced Lung Cancer after Chemotherapy with/without Radiation Therapy: Can It Predict Treatment Responsiveness of the Tumor?
Yoo, M. R., Whang, S. H., Park, C. H., Kim, S. J., & Kim, T. H. (2013) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2013.69.2.131
Pharmacotherapy for treatment of lung cancer in the elderly
van Veggel, B. A. M. H., Biesma, B., & Smit, E. F. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1028357
Paclitaxel, Carboplatin, and Bevacizumab
Furst, J. M., Solimando, D. A., & Waddell, J. A. (2011) · Hospital Pharmacy · doi:10.1310/hpj4606-406
Clinical Issues and Treatment of Lung Cancer in Mexico
Carmona, R. E., Mendoza-Posada, D. A., Camacho-Mendoza, C., & Sánchez-Campos, O. R. (2012) · Journal of Analytical Oncology · doi:10.6000/1927-7229.2012.01.01.9
Maintenance therapy for patients with advanced non-small cell lung cancer: fact or myth?
Dediu, M. (2011) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-011-0244-9
Role of erlotinib in the treatment of advanced non-small-cell lung cancer patients with EGFR wild-type tumors
Braun, E., & Bonomi, P. (2014) · Lung Cancer Management · doi:10.2217/lmt.13.74
Driver mutations as predictive biomarkers in lung cancer
Girard, N. (2012) · Current Respiratory Care Reports · doi:10.1007/s13665-011-0001-x
Predictive value of the early metabolic response in patients with advanced-stage non-small cell lung cancer
Moreno, C., Mourelo, S., Soler, M., Moragas, M., RIERA, E., & Garcia, J. R. (2014) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2014.06.019
Pemetrexed in Heavily Pretreated Non-Small-Cell Lung Cancer Patients: Case Report and Review of the Literature
Tartarone, A. (2010) · Future Oncology · doi:10.2217/fon.10.146
A surgical intervention followed by adjuvant treatment of erlotinib for a 85-year-old elderly advanced lung cancer
Ayabe, T., Shimizu, T. M., Tomita, M., & Onitsuka, T. (2012) · Annals of Cancer Research and Therapy · doi:10.4993/acrt.20.01
Is there a role for maintenance therapy in advanced non-small-cell lung cancer?
Gridelli, C., Maione, P., Rossi, A., Schettino, C., Bareschino, M. A., Sacco, P. C., Palazzolo, G., Casaluce, F., Sgambato, A., & Ciardiello, F. (2012) · Clinical Practice · doi:10.2217/cpr.11.126
Chemotherapy of advanced non-small-cell lung cancer: current landscape
Pallis, A. G., Dziadziuszko, R., & O'Brien, M. E. R. (2013) · Clinical Investigation · doi:10.4155/cli.13.6
Cancer du poumon non à petites cellules : Thérapies actuelles et perspectives moléculaires
Boumedien, F. (2014) · Pharmactuel
Third-line systemic treatment for non-small cell lung cancer
Kim, S. C. H., Paget‐Bailly, S., Trinquart, L., Calais, F., Bonnetain, F., & Westeel, V. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011291
The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
Song, I., Lee, H. J., Yang, Y.-J., Choi, Y.-S., Ryu, H.-W., Lee, M.-W., Moon, J. Y., Jo, D., Kim, S., & Yun, H. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.316
Maintenance therapy for advanced non-small cell lung cancer (NSCLC)
Paget‐Bailly, S., Paulus, V., Pana-Katatali, H., Agazzi, G. M., Trinquart, L., Calais, F., & Westeel, V. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011631
Retracted
DISCOVERY AND VALIDATION OF PROTEIN BIOMARKERS FOR LUNG CANCER
Petris, L. D. (2010) · Figshare
Valor predictivo de la respuesta metabólica precoz en pacientes con cáncer de pulmón de célula no pequeña en estadio avanzado
Moreno, C., Mourelo, S., Soler, M., Moragas, M., RIERA, E., & Garcia, J. R. (2014) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2013.10.013
Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study
Massa, I., Nanni, O., Guidoboni, M., Frassineti, G. L., Rocca, A., Burgio, M. A., Valmorri, L., Marri, M., Piancastelli, A., Faedi, M., et al. (2015) · Oncology Letters · doi:10.3892/ol.2015.3967
Next-Generation Sequencing in the Era of Cancer-Targeted Therapies: Towards the Personalised Medicine
Albukhari, A., Bokhari, F. F., & Choudhry, H. (2015) · Springer eBooks · doi:10.1007/978-3-319-15811-2_3
ORAL CHEMOTHERAPY IN ELDERLY PATIENTS WITH ADVANCED NON SMALL CELL LUNG CARCINOMA
Bordonaro, S., Vizzini, L., Spinnato, F., Antonelli, G., Caruso, M., Sciacca, D., Butera, A., Cappuccio, F., Gebbia, V., Ferraù, F., et al. (2014)
Place d'un traitement combiné par radiofréquence et radiothérapie thoracique dans la prise en charge des cancers bronchiques non à petites cellules
Debiton-Morin, C. (2014) · HAL
Cadm 1's expression levels in peripheral blood: A potential marker for diagnosis, disease progression and clicical outcome for NSCLC.
Branco, M. T. C. R. T. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/t6p5-dy59
Special report: maintenance therapy in advanced non-small-cell lung cancer.
Gutman, S. (2011) · PubMed
[Sequential Treatment of Advanced Squamous Lung Cancer: First-line Gemcitabine +/- platinum Followed by Second-line Taxanes +/- platinum Versus Reverse Sequence].
Xu, J., Liu, X., Gao, H., Guo, W., Tang, C., Li, X., Li, J., Qin, H., Wang, W., Qu, L., et al. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.05.09
Shifting the Paradigm for Maintenance Therapy for Non-small-cell Lung Cancer
Lee, V. H.-F. (2010) · The HKU Scholars Hub (University of Hong Kong)
Usage of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in Tumor EGFR Wild-Type or Unknown Non-Small Cell Lung Cancer
Chen, Y., Perng, R.-P., & Whang‐Peng, J. (2013) · doi:10.6323/jocrp.2013.29.1.1
Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer
LuoShiang, J., & LeawYing, J. (2011)
Maintenance therapy
Gridelli, C. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835ca1c3
Immunohistochemical study of Napsin A and thyroid transcription factor-1 in non-small-cell lung carcinoma
Tawfik, H. M., Farghaly, E. A., & Gad, Y. A. (2012) · Egyptian Journal of Pathology · doi:10.1097/01.xej.0000415808.32127.71
Therapeutic advances in non-small cell lung cancer: Highlights from the annual clinical cancer conferences
Langer, C. J., & Socinski, M. A. (2011) · Community Oncology · doi:10.1016/s1548-5315(12)70045-1
Tratamento de manutenção em câncer de pulmão não pequenas células avançado - relato de caso
Peter, A. (2010)
Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors
Vázquez‐Estévez, S., Villanueva, M. J., Fírvida, J. L., Campos, B., Lázaro, M., Huidobro, G., Areses, M. D. C., Fernández, N., Covela, M., & Casal, J. (2015) · Journal of Analytical Oncology · doi:10.6000/1927-7229.2015.04.03.1
Circulating tumour cells and EpCAM as tools for diagnostic and mechanistic studies of lung cancer
Tay, A. (2015) · doi:10.25560/25756
L’oncogériatrie en cancérologie thoracique : extension du domaine de la concertation
Pujol, J. L. (2011) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2011.06.013
Erlotinib or Chemotherapy in Second-Line or Later Treatment of Tumor EGFR Wild-Type Pulmonary Adenocarcinoma Patients
Chen, Y., Luo, Y., Wu, C., Lee, Y., Perng, R.-P., & Whang‐Peng, J. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.6323/jcrp.2015.2.1.01
Phosphatidylinositol 3-Kinase (PI3K) as a therapeutic target in NSCLC
Stamatkin, C. W. (2014) · UKnowledge (University of Kentucky)
Personalized Management of Lung Cancer
Komaki, R. R. (2013) · doi:10.2217/9781780842165
First-line therapy of advanced non-small cell lung cancer not harboring an activating EGFR mutation
Gridelli, C., & Rossi, A. (2012) · Informa Healthcare eBooks · doi:10.3109/9781841848679.006
The Use, Effectiveness, and Safety of Bevacizumab In Older Adults With Advanced Stage Non-Small Cell Lung Cancer
Katz, A. J. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/praa-m387
Interleukin-15 based maintenance of metabolic homeostasis and treatment of lung cancer
Sun, H. (2016)
Considerations of practice guidelines and recommendations
Bi, N., & Kong, F. (2013) · doi:10.2217/ebo.13.197
DNA-targeted drugs
Meza–Junco, J., & Sawyer, M. B. (2011) · doi:10.2217/ebo.11.251
EGF receptor-targeted drugs
Mitsudomi, T. (2011) · doi:10.2217/ebo.11.228
Lung Cancer in Older Adults: Systemic Treatment
Quoix, É. (2018) · Springer eBooks · doi:10.1007/978-3-319-44870-1_31-1
Respiratory Organ Aging and Cancer
Witt, L. J., & Presley, C. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-44870-1_63-1
Extracellular vesicles : mediators of immune modulation in the lung and as therapeutic vehicles
Ullsten-Wahlund, C. (2018) · Figshare
Identifying Potential Dual Inhibitory Candidates for Non-Small Cell Lung Cancer through Molecular Docking, 3D-QSAR Pharmacophore-based Virtual Screening, Comparative Molecular Field and Similarity Indices Analysis Modeling
Zhu, X., Li, Y., Zhang, X. R., Yuan, L., Luo, P. H., Gao, X., & Tan, Z. S. (2018) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2018/44771
Chimiothérapie de première ligne incluant le traitement de maintenance et les anti-angiogéniques dans les CBNPC avancés en l’absence d’addiction oncogénique
Pérol, M., Swalduz, A., Paulus, V., & Avrillon, V. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30033-8
Stratégie thérapeutique initiale dans les cancers bronchiques non à petites cellules
Westeel, V., Jacoulet, P., & Marescaux, A. (2011) · Springer eBooks · doi:10.1007/978-2-287-99041-0_7
Cáncer de pulmón primario
Boyer, A., Tomasini, P., Fournier, C., Greiller, L., Barlési, F., & Mascaux, C. (2019) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(19)42732-3
[Lung Adenocarcinomas with Pulmonary Miliary Metastases: A Case Report and Literature Review].
Li, L., Zhou, L., & Zhang, J. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.12.11
Erkrankungen der Atmungsorgane
(2011) · Elsevier eBooks · doi:10.1016/b978-3-437-22702-8.50007-8
Les traitements de maintenance dans les cancers bronchiques non a petites cellules metastatiques en 2012 Maintenance therapy in advanced non-small cell lung cancer in 2012
Pérol, M. (2012)
Clinical observation of Pemetrexed first-line treatment in advanced non-squamous lung cancer or non-small cell lung cancer without driver-mutations: a phase 2, single-arm trial
Sha, Z., He, J., Jiang, Q., Xu, L., Hu, L., Liang, Z., Li, T., Zhong, L., Yu, Q., Pei, X., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6539
Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials
Zhou, J. J. L., HuangZhaohui, R., & Zhan, C. (2013)
Experience of pemetrexed in maintenance therapy for metastatic lung adenocarcinoma
Vladimirova, L. Y., Эдуардовна, С. А., Kalabanova, E. A., Meshcheryakov, P. N., Oskin, S. V., Kabanov, S. N., Samaneva, N. Y., Svetitskaya, Y. V., & Викторовна, Т. А. (2021) · South Russian Journal of Cancer · doi:10.37748/2686-9039-2021-2-1-4
Real-world data suggest that geriatric assessment fails to stratify risk in treating older adults with lung cancer
Donadio, M. D. S., de Oliveira, A. C. F., Moura, L. L., de Jesus, V. H. F., Felismino, T. C., & Dettino, A. L. A. (2021) · Brazilian Journal of Oncology · doi:10.5935/2526-8732.20210030
Les traitements de maintenance dans les cancers bronchiques non à petites cellules métastatiques en 2012
Pérol, M. (2012) · ONCOLOGIE · doi:10.1007/s10269-012-2156-7
Oncologie thoracique
Cortot, A. B., Dansin, É., & Scherpereel, A. (2011) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(11)70056-8
Chemotherapy
Rudney, R., & Daeninck, P. J. (2021) · Oxford University Press eBooks · doi:10.1093/oso/9780198837008.003.0022
References
Brown, S. R., Gregory, W. M., Twelves, C., & Brown, J. (2014) · doi:10.1002/9781118763612.refs
Oncologie thoracique
Scherpereel, A., & Dansin, É. (2010) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(10)70045-8
Updated treatment guidelines for stage IV NSCLC
(2009) · PharmacoEconomics & Outcomes News · doi:10.2165/00151234-200905930-00003
A Meta-Analysis of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer
张, 庚. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.125679
Cancer of the Lung
Morgensztern, D., Boffa, D. J., Chen, A. J., Dhanasopon, A. P., Goldberg, S. B., Decker, R. H., Devarakonda, S. H. K., Ko, J. P., Soto, L. M. S., Waqar, S. N., et al. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm085.pub2
Data from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
Nagji, A. S., Cho, S.-H., Liu, Y., Lee, J. K., & Jones, D. R. (2023) · doi:10.1158/1535-7163.c.6531740
Natural Products as Cytotoxic Agents
Pullman, M. K., León, F., & Cutler, S. J. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc216.pub2

Authors: Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., Nordquist, L., Pfister, D. G., Piantadosi, S., Schiller, J. H., Smith, R., Smith, T. J., Strawn, J. R., Trent, D., & Giaccone, G.
Affiliations: American Society of Clinical Oncology (US)
ORCID: Azzoli, Christopher G.
Temin, Sarah
Pao, William
Brahmer, Julie
Johnson, David H.
Masters, Gregory
Pfister, David G.
Piantadosi, Steven
Schiller, Joan H.
Smith, Thomas J.
Giaccone, Giuseppe
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-12-20
Volume: 27
Issue: 36
Pages: 6251-6266
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.23.5622
PMC: PMC2793036
OpenAlex: W2119366998
Cited by: 915
References: 218
Citations by year: 2026: 6 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 25 · 2020: 21 · 2019: 33 · 2018: 38 · 2017: 38 · 2016: 67 · 2015: 89 · 2014: 111 · 2013: 128 · 2012: 119
FWCI: 90.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: stage IV non-small cell lung cancer, chemotherapy, first-line therapy, second-line therapy, third-line therapy, gefitinib, erlotinib, bevacizumab, carboplatin-paclitaxel, cetuximab, docetaxel, EGFR mutation, platinum-based doublets, overall survival, progression-free survival, treatment toxicity
MeSH terms: Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Staging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks